CO5700712A2 - Prevencion y tratamiento de la enfermedad de alzheimer - Google Patents

Prevencion y tratamiento de la enfermedad de alzheimer

Info

Publication number
CO5700712A2
CO5700712A2 CO05056010A CO05056010A CO5700712A2 CO 5700712 A2 CO5700712 A2 CO 5700712A2 CO 05056010 A CO05056010 A CO 05056010A CO 05056010 A CO05056010 A CO 05056010A CO 5700712 A2 CO5700712 A2 CO 5700712A2
Authority
CO
Colombia
Prior art keywords
alkyl
propyl
butyl
ethyl
bile acid
Prior art date
Application number
CO05056010A
Other languages
English (en)
Inventor
Thierry Canton
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of CO5700712A2 publication Critical patent/CO5700712A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

1.- Aplicación de compuestos inhibidores de recaptura de ácidos biliares para la preparación de un medicamento que permita prevenir o tratar la enfermedad de Alzheimer.2.- Aplicación según la reivindicación 1, caracterizada porque los inhibidores de recaptura de ácidos biliares son compuestos de fórmula (lA):en la cual:R1 representa metilo, etilo, propilo o butilo;R2 representa H, OH, NH2 o NH-alquilo C1-C6;R3 es un monosacárido, bisacárido, trisacárido o tetrasacárido, en que dicho radical está sin sustituir o mono- o poli-sustituido con un grupo protector de azúcares;R4 es metilo, etilo, propilo o butilo;R5 es metilo, etilo, propilo o butilo;Z es (C=O)n-alquilo (C0-C16); (C=O)n-alquilo (CO-C16)-NH; (C=O)n-alquilo (C0-C16)-O; (C=O)n-alquilo (C0-C16)-(C=O)- o un enlace covalente;n es 0 ó 1;m es 0 ó 1;así como sus sales por adiciones farmacéuticamente aceptables.3.- Aplicación según la reivindicación 1 ó 2, caracterizada porque el inhibidor de recaptura de ácidos biliares es el compuesto de fórmula (lA) siguiente:
CO05056010A 2002-12-12 2005-06-09 Prevencion y tratamiento de la enfermedad de alzheimer CO5700712A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0215722A FR2848452B1 (fr) 2002-12-12 2002-12-12 Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer

Publications (1)

Publication Number Publication Date
CO5700712A2 true CO5700712A2 (es) 2006-11-30

Family

ID=32338722

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05056010A CO5700712A2 (es) 2002-12-12 2005-06-09 Prevencion y tratamiento de la enfermedad de alzheimer

Country Status (22)

Country Link
EP (1) EP1572174A1 (es)
JP (1) JP2006514063A (es)
KR (1) KR20050084250A (es)
CN (1) CN1726016A (es)
AR (1) AR042354A1 (es)
AU (1) AU2003296802A1 (es)
BR (1) BR0317280A (es)
CA (1) CA2507945A1 (es)
CO (1) CO5700712A2 (es)
FR (1) FR2848452B1 (es)
HR (1) HRP20050534A2 (es)
MA (1) MA27500A1 (es)
MX (1) MXPA05005556A (es)
NO (1) NO20053341L (es)
NZ (1) NZ540496A (es)
PE (1) PE20040770A1 (es)
PL (1) PL377110A1 (es)
RS (1) RS20050420A (es)
RU (1) RU2005121909A (es)
TW (1) TW200503707A (es)
WO (1) WO2004062652A1 (es)
ZA (1) ZA200504656B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
NZ546887A (en) 2003-11-03 2009-04-30 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
EP1713780B1 (en) 2004-02-05 2012-01-18 Probiodrug AG Novel inhibitors of glutaminyl cyclase
EP1812007B1 (en) 2004-11-02 2011-09-07 Northwestern University Pyridazine compounds and methods
US8158627B2 (en) 2006-04-28 2012-04-17 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
AR066664A1 (es) * 2007-05-22 2009-09-02 Otsuka Pharma Co Ltd Un medicamento para tratar enfermedad de alzheimer
BR112014010228B1 (pt) * 2011-10-28 2020-09-29 Lumena Pharmaceuticals Llc Uso de inibidores de reciclagem de ácido biliar para o tratamento de hipercolemia e doença hepática colestática
EA201891154A1 (ru) 2011-10-28 2019-02-28 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2040996A1 (en) * 1990-05-02 1991-11-03 Robert L. Albright Composition and method for controlling cholesterol
CA2104594C (en) * 1991-02-22 2004-05-11 Howard K. Shapiro Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
US6383500B1 (en) * 1996-06-27 2002-05-07 Washington University Particles comprising amphiphilic copolymers, having a crosslinked shell domain and an interior core domain, useful for pharmaceutical and other applications
US5985936A (en) * 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
ES2257824T3 (es) * 1998-01-28 2006-08-01 Warner-Lambert Company Llc Metodo para tratar la enfermedad de alzheimer.
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19825804C2 (de) * 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
US20010028895A1 (en) * 2000-02-04 2001-10-11 Bisgaier Charles L. Methods of treating alzheimer's disease
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents

Also Published As

Publication number Publication date
NO20053341L (no) 2005-09-07
KR20050084250A (ko) 2005-08-26
MXPA05005556A (es) 2005-07-26
PL377110A1 (pl) 2006-01-23
AU2003296802A1 (en) 2004-08-10
RU2005121909A (ru) 2006-01-20
CN1726016A (zh) 2006-01-25
HRP20050534A2 (en) 2006-11-30
WO2004062652A1 (fr) 2004-07-29
RS20050420A (en) 2007-04-10
ZA200504656B (en) 2006-08-30
NO20053341D0 (no) 2005-07-08
JP2006514063A (ja) 2006-04-27
FR2848452B1 (fr) 2007-04-06
FR2848452A1 (fr) 2004-06-18
TW200503707A (en) 2005-02-01
NZ540496A (en) 2008-04-30
BR0317280A (pt) 2005-11-08
CA2507945A1 (fr) 2004-07-29
PE20040770A1 (es) 2004-12-10
AR042354A1 (es) 2005-06-15
MA27500A1 (fr) 2005-08-01
EP1572174A1 (fr) 2005-09-14

Similar Documents

Publication Publication Date Title
BR0312999A (pt) Compostos, composições farmacêticas, método para aumentar a cognição, de tratamento, de inibição da atividade de enzima pde4 em um paciente
UY28674A1 (es) Inhibidores heterociclil amino de 11-beta-hidroxiesteroide deshidrogenasa tipo 1
BR0010555A (pt) Inibidores de neuraminidases
HUP0301427A2 (hu) Fotokemoterápiában alkalmazható fotoszenzitizáló, 5-aminolevulinsavészterek azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
TW200420549A (en) Thiazole derivatives
CO5611108A2 (es) Benzazoles sustituidos y su aplicacion como inhibidores quinasa raf
NZ580226A (en) Dimer compounds as inhibitors of iap
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
WO2008002573A3 (en) Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
BRPI0409624A (pt) 2-hidróxi-3-diaminoalcanos de benzamida
DE60130023D1 (de) Behandlung der nebenwirkungen von statinen
PE20061332A1 (es) Derivados de piperidina como agentes inhibidores de la renina
MX2009008779A (es) Composicion farmacéutica que comprende derivado de pirazina y método para usar el derivado de pirazina en combinación.
TWI265929B (en) Triazinyl derivatives for inhibiting the production of IL-12
TW200510311A (en) CCr8 inhibitors
CR20230052A (es) Combinaciones para el tratamiento de cáncer.
ATE427941T1 (de) Thiazolderivate mit vap-1-hemmender wirkung
CO5031242A1 (es) Derivados de cromanona y tiocromanona, proceso para su preparacion y composicion farmaceutica que los comprende
CO5700712A2 (es) Prevencion y tratamiento de la enfermedad de alzheimer
GEP20125548B (en) New dihidroindolone compounds, a process for its preparation and pharmaceutical compositions containing them
HK1127476A1 (en) Pyrazolopyrimidine derivative
TW200745048A (en) Novel benzimidazole and benzothiazole derivatives, preparation process therefor, application thereof as medicaments, pharmaceutical compositions and novel use especially as CMET inhibitors
NO20060277L (no) Anvendelse av bisyklo [2.2.1] heptanderivater til fremstilling av nevrobeskyttende farmasoytiske sammensetninger
AR035285A1 (es) Formulaciones en combinacion de derivados de1,4-benzotiepina-1,1-dioxido con otras sustancias activas, y su utilizacion.
AR065724A1 (es) Macrolidos

Legal Events

Date Code Title Description
FC Application refused